RT Journal Article
SR Electronic
T1 The impact of COVID-19 disruption to cervical cancer screening in England on excess diagnoses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20240754
DO 10.1101/2020.11.30.20240754
A1 Castanon, Alejandra
A1 Matejka, Rebolj M
A1 Pesola, Francesca
A1 Sasieni, Peter
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.30.20240754.abstract
AB Background Cervical cancer screening services in England have been disrupted by the COVID-19 pandemic.Methods Using routine statistics we estimate number of women affected by delays to screening. We used published research to estimate the proportion of screening age women with high-grade cervical intraepithelial neoplasia and progression rates to cancer. Under two scenarios we estimate the impact of COVID-19 on cervical cancer over one screening cycle (3y at ages 25-49 and 5y at ages 50-64). The duration of disruption in both scenarios is six months. In the first scenario all women have their screening interval is extended by six months. In the second some women (those who would have been screened during the disruption) miss one screening cycle, but most women have no delay.Results Both scenarios result in similar numbers of excess cervical cancers: 630 vs. 632 (both 4.3 per 100,000 women in the population). However the scenario in which some women miss one screening cycle creates inequalities - they would have much higher rates of excess cancer: 41.5 per 100,000 screened women compared to those with a six month delay (5.9 per 100,000 screened).Conclusion To ensure equity for those affected by COVID-19 related screening delays additional screening capacity will need to be paired with prioritising the screening of overdue women.Competing Interest StatementMR declares that her employer received honoraria from Hologic for lectures on her behalf. PS has received personal fees from Hologic and non-financial support from PreventX outside the submitted work. AC and PF declare no conflict of interest.Funding StatementAC, MR,FP and PS are supported by Cancer Research UK [grant number C8162/A16892 to PS for AC and MR and grant number: C8162/A25356 to PS for FP]. The funder had no role in the preparation of the manuscript or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not required for this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yessource data for this study is freely available in published literature.